Full Text View
Tabular View
No Study Results Posted
Related Studies
Women's Isoflavone Soy Health (WISH) Trial
This study is ongoing, but not recruiting participants.
First Received: July 7, 2005   Last Updated: August 14, 2008   History of Changes
Sponsors and Collaborators: National Center for Complementary and Alternative Medicine (NCCAM)
Office of Dietary Supplements (ODS)
Office of Research on Women's Health (ORWH)
Solae Company
Information provided by: National Center for Complementary and Alternative Medicine (NCCAM)
ClinicalTrials.gov Identifier: NCT00118846
  Purpose

The purpose of this study is to determine whether soy supplements can reduce hardening of the arteries in postmenopausal women. This study will also determine the effects of soy supplements on mental processes, bone mineral density, and breast tissue density.


Condition Intervention Phase
Atherosclerosis
Cardiovascular Diseases
Heart Diseases
Osteoporosis
Menopause
Breast Cancer
Dementia
Dietary Supplement: 25 g soy protein supplement
Other: Matching placebo
Phase II
Phase III

Study Type: Interventional
Study Design: Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Phytoestrogens and Progression of Atherosclerosis

Resource links provided by NLM:


Further study details as provided by National Center for Complementary and Alternative Medicine (NCCAM):

Primary Outcome Measures:
  • Progression of subclinical atherosclerosis measured by the rate of change in distal common carotid artery far wall intima-media thickness in computer image processed B-mode ultrasonograms [ Time Frame: Baseline and every 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Longitudinal change in cognitive function, bone mineral density, and mammographic percent density [ Time Frame: Cognitive function: Baseline and end-of-study; Bone mineral density: Baseline, 12 month, 30 month; Mammographic percent density: Baseline, 12 month, 24 month ] [ Designated as safety issue: No ]

Enrollment: 350
Study Start Date: March 2004
Estimated Study Completion Date: June 2009
Estimated Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
25 gm soy protein administered twice daily in equivalent dosages (12.5 gm)
Dietary Supplement: 25 g soy protein supplement
25 g soy protein admisitered in equally divided dosage twice daily
2: Placebo Comparator
Matching placebo
Other: Matching placebo
Milk protein administered twice daily

Detailed Description:

Heart disease is the leading cause of death among women in the United States. Atherosclerosis, a primary cause of heart disease, accounts for more than 485,000 heart attacks and 370,000 strokes each year in American women. Data indicate that a woman's risk of suffering from an atherosclerosis-related cardiovascular event significantly increases after menopause; this risk may be due to reduced estrogen production associated with menopause. Soy isoflavones are plant compounds that are structurally similar to human estrogen. Evidence suggests that soy supplements may provide the same protection against heart disease as estrogen in postmenopausal women. This study will determine the effects of soy supplements on atherosclerosis progression, cognition, bone mineral density, and breast tissue density changes in postmenopausal women.

This study will last 2.5 years. Participants will be randomly assigned to receive either soy supplements or placebo daily for the duration of the study. The active product, which will be given as two divided doses, is 25 g soy protein containing 85 mg aglycone weight naturally-occurring isoflavones (150 mg total isoflavone), genistein 45 mg aglycone weight (80 mg total weight), daidzein 35 mg aglycone weight (60 mg total weight) and glycitein 5 mg aglycone weight (10 mg total weight). Blood collection, cognitive tests, and mammograms will be used to assess participants at study entry, at each monthly visit, and at study completion.

  Eligibility

Ages Eligible for Study:   30 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Postmenopausal, defined as having no vaginal bleeding for at least 1 year and having a serum estradiol level higher than 20 pg/ml

Exclusion Criteria:

  • Signs or history of cardiovascular disease
  • Diabetes mellitus or fasting serum glucose of 140 mg/dL or greater
  • Plasma triglyceride levels of 500 mg/dL or greater
  • Serum creatinine greater than 2.0 mg/dL
  • Uncontrolled hypertension
  • Untreated thyroid disease
  • Life expectancy less than 5 years
  • Current use of hormone replacement therapy (HRT)
  • Soy- or nut-related food allergies
  • Follow a vegan diet
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00118846

Locations
United States, California
University of Southern California Keck School of Medicine
Los Angeles, California, United States, 90033
Sponsors and Collaborators
Solae Company
Investigators
Principal Investigator: Howard N. Hodis, MD University of Southern California Keck School of Medicine
  More Information

Additional Information:
No publications provided

Responsible Party: University of Southern California ( Howard N. Hodis )
Study ID Numbers: U01 AT001653, U01 AT001653-02S2, U01 AT001653-02S4, U01 AT001653-02S5
Study First Received: July 7, 2005
Last Updated: August 14, 2008
ClinicalTrials.gov Identifier: NCT00118846     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Center for Complementary and Alternative Medicine (NCCAM):
Women
Complementary and Alternative Medicine
CAM

Study placed in the following topic categories:
Atherosclerosis
Arterial Occlusive Diseases
Heart Diseases
Skin Diseases
Disease Progression
Vascular Diseases
Central Nervous System Diseases
Breast Neoplasms
Osteoporosis
Bone Diseases, Metabolic
Arteriosclerosis
Brain Diseases
Bone Diseases
Cognition Disorders
Delirium, Dementia, Amnestic, Cognitive Disorders
Musculoskeletal Diseases
Mental Disorders
Phytoestrogens
Dementia
Menopause
Breast Diseases
Delirium

Additional relevant MeSH terms:
Atherosclerosis
Arterial Occlusive Diseases
Heart Diseases
Skin Diseases
Nervous System Diseases
Vascular Diseases
Central Nervous System Diseases
Breast Neoplasms
Osteoporosis
Bone Diseases, Metabolic
Arteriosclerosis
Brain Diseases
Bone Diseases
Neoplasms
Delirium, Dementia, Amnestic, Cognitive Disorders
Neoplasms by Site
Musculoskeletal Diseases
Mental Disorders
Cardiovascular Diseases
Dementia
Breast Diseases

ClinicalTrials.gov processed this record on September 09, 2009